This is VAERS ID 619248

Administered by: Other       Purchased by: Other
Symptoms: Decreased immune responsiveness, Granulocytes maturation arrest, Neutropenia, Neutrophil count decreased, Pain, Pyrexia, White blood cell count decreased
SMQs:, Haematopoietic leukopenia (narrow), Neuroleptic malignant syndrome (broad), Systemic lupus erythematosus (broad), Anticholinergic syndrome (broad), Myelodysplastic syndrome (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 5 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: March 2015: leukocyte count: 2.180 mm/3: low leucocyte count reported as severe neutropenia. 03/19/2015, Body temperature, fever; 03/2015, Laboratory test, granulocyte maturation blockade; 03/2015, White blood cell count, 2.180/mm3, decreased.
CDC Split Type: WAES1511BRA014674

Write-up: This spontaneous report was received from a consumer and lawyer via a company representative, referring to a case in litigation regarding a female patient of unknown age. The patient''s medical history and concurrent conditions were not reported. On 27-FEB-2015, the patient was vaccinated with GARDASIL 0.5 ml, intramuscular (lot# and expiration date were not reported). Concomitant therapy was not reported. On an unspecified date in February 2015, the patient experienced body pain. Subsequently on 18-MAR-2015, the patient visited her physician and a leucocyte count was performed and the result was low leukocyte count, reported as severe neutropenia (2.180 unit reported as mm/3). On 19-MAR-2015 the patient experienced fever and general clinical chart worsening and was hospitalized. During the hospitalization the patient''s hematologist reported granulocyte maturation blockade and prescribe an unknown medication to increased the leukocyte count. Also during the hospitalization the patient''s physician reported patient''s blocking the production of leukocyte setting patient''s life a risk (life threatening) once that the patient was presenting low immune response. The reporter related the blocking the production of leukocyte to the therapy with GARDASIL. On 23-MAR-2015 the patient was discharged from hospital. The outcome of body pain, severe neutropenia, fever, general clinical chart worsening, granulocyte maturation blockade, blocking the production of leucocyte and low immune response was unknown. The relatedness of body pain, severe neutropenia, fever, general clinical chart worsening, granulocyte maturation blockade, and low immune was not reported for GARDASIL. Additional information is not expected once that the case is a litigation case.